Inovio pharmaceuticals stock.

Find out the direct holders, institutional holders and mutual fund holders for Inovio Pharmaceuticals, Inc. (INO).Galectin Therapeutics Inc. 1.99. -0.13. -6.13%. Get Inovio Pharmaceuticals Inc (INO:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Find the latest Inovio Pharmaceuticals, Inc. (0A43.L) stock quote, history, news and other vital information to help you with your stock trading and investing.Jun 27, 2022 · Inovio Pharmaceuticals (INO-5.75%) stock rose slightly on an otherwise gloomy day for the wider market. Investors were cheered by the appointment of a new chief medical officer at their company. Inovio Pharmaceuticals (INO) stock price prediction is 2.5270197612807 USD. The Inovio Pharmaceuticals stock forecast is 2.5270197612807 USD for 2024 ...

At INOVIO, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section. If you experience any issues with this process, please contact us for further assistance.WebSee Inovio Pharmaceuticals, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. ... Inovio Pharmaceuticals, Inc. INO NASDAQ. INO NASDAQ. INO NASDAQ. INO NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview News Ideas Financials …Web

Inovio Pharmaceuticals stock has received a consensus rating of hold. The average rating score is and is based on 0 buy ratings, 5 hold ratings, and 1 sell ratings. What was the 52-week low for ... Nasdaq 14,295.90 +0.39% +54.88 Russell 1,801.91 +0.042% +0.76 VIX 12.68 -0.079% -0.0100 Home INO • NASDAQ Inovio Pharmaceuticals Inc Follow Share $0.40 Nov 28, 11:47:07 AM GMT-5 · USD ·...

Inovio Pharmaceuticals ( INO) reported Q3 2023 earnings per share (EPS) of -$0.13, meeting estimates of -$0.13 by 0.29%. In the same quarter last year, Inovio Pharmaceuticals 's earnings per share (EPS) was -$0.15. Inovio Pharmaceuticals is expected to release next earnings on 02/28/2024, with an earnings per share (EPS) …WebCost-saving measures include 11% headcount reduction Annual savings expected to be approximately $4.3 million Data readouts expected in first quarter of 2023 for key programs including INO-3107 for RRP and VGX-3100 for cervical HSIL INOVIO ( NASDAQ : INO ), a biotechnology company focused on developing and commercializing …ROBERT J. JUBA JR. “INOVIO’s team has extensive experience manufacturing DNA medicines and a proven track record of producing them at unprecedented speeds.”. “INOVIO’s CELLECTRA® intramuscular and intracellular smart devices have allowed us to deliver our optimized DNA plasmids directly into cells in the body to produce immune responses.Inovio Pharmaceuticals is a biotechnology company that focuses on bringing to market ... certification on behalf of Inovio stock purchasers from February 14, 2020 ...

Get Inovio Pharmaceuticals Inc (INO.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Actinium Pharmaceuticals (ATNM – Research Report) and Inovio Pharmaceuticals (INO – Research Report).Actinium ...Web

In a major shakeup at Inovio Pharmaceuticals, company co-founder J. Joseph Kim is out as CEO. ... In early morning trading, Inovio's stock was down more than 31% at $1.72 per share.Oct 27, 2022 · Inovio Pharmaceuticals is a small-ish biotech company with a market cap of around $519 million. The company ended 2022's second quarter with $348 million in cash and short-term investments, which ... Dec 17, 2021 · The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the last month ... ROBERT J. JUBA JR. “INOVIO’s team has extensive experience manufacturing DNA medicines and a proven track record of producing them at unprecedented speeds.”. “INOVIO’s CELLECTRA® intramuscular and intracellular smart devices have allowed us to deliver our optimized DNA plasmids directly into cells in the body to produce immune responses.Nov 29, 2023 · 1 Wall Street analysts have issued twelve-month target prices for Inovio Pharmaceuticals' stock. Their INO share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 423.3% from the stock's current price.

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its ... INO is the ticker symbol for Inovio Pharmaceuticals, Inc., a biotechnology company that develops and commercializes DNA medicines to treat and protect people from HPV-associated diseases, cancer, and infectious diseases. The web page shows its stock price, news, analysis, and performance outlook on NasdaqGS. View today's Inovio Pharmaceuticals Inc stock price and latest INO news and analysis. Create real-time notifications to follow any changes in the live stock ...INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program 10-10 - 1 view Inovio Pharmaceuticals, Inc. Stock Option Grant Notice (2023 Omnibus Incentive Plan) 08-09 - 1 view Inovio Pharmaceuticals, Inc. RSU Award Grant Notice (2023 Omnibus Incentive …WebAug 9, 2023 · Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling resources and headcount to align with strategic focus on INO-3107 and late-stage clinical candidates closest to market and with greatest opportunity to deliver on the promise of DNA medicines for ...

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program 10-10 - 1 view Inovio Pharmaceuticals, Inc. Stock Option Grant Notice (2023 Omnibus Incentive Plan) 08-09 - 1 view Inovio Pharmaceuticals, Inc. RSU Award Grant Notice (2023 Omnibus Incentive …Web0.3950. +0.0050. +1.28%. INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer ...

Inovio Pharmaceuticals Inc (INO) stock is trading at $0.86 as of 10:19 AM on Tuesday, Mar 28, a drop of -$0.05, or -5.9% from the previous closing price of $0.91. The stock has traded between $0.79 and $0.91 so far today. Volume today is less active than usual.According to the issued ratings of 1 analysts in the last year, the consensus rating for Inovio Pharmaceuticals stock is Hold based on the current 1 hold rating for INO. The average twelve-month price prediction for Inovio Pharmaceuticals is $2.00 with a high price target of $2.00 and a low price target of $2.00.Three months after bringing on a new CEO, Inovio has reached a settlement with investors over accusations that it exaggerated progress on its Covid-19 vaccine candidate. The biotech, once claiming ...WebYou may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.It's been a rough 12 months for Inovio Pharmaceuticals (INO-3.67%).In the past year, shares of the company have declined by 35% while the S&P 500 has risen 30%. The main reason for this abysmal ...As the deadly new virus spread globally, Inovio Pharmaceuticals, a small biotech company in Pennsylvania, rushed to develop a vaccine. After announcing promising early results, Inovio’s stock ...As of June 30, 2022, Inovio had 247.5 million shares of common stock outstanding and 267.8 million shares of common stock outstanding on a fully diluted basis. Total operating expenses were $104.9M.

Overview Stock Screener Earnings Calendar Sectors Nasdaq | INO U.S.: Nasdaq Inovio Pharmaceuticals Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 22, 2023 7:33 p.m....

After market hours on Tuesday, Inovio revealed that it booked revenue of $839,000 in its fourth quarter of 2021, well down from the $5.6 million in the same quarter the previous year. The net loss ...

Find out all the key statistics for Inovio Pharmaceuticals, Inc. (INO), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. About the company. INO fundamental analysis.Inovio Pharmaceuticals is a biotechnology company that focuses on bringing to market ... certification on behalf of Inovio stock purchasers from February 14, 2020 ...Inovio Pharmaceuticals Inc (INO) stock is trading at $0.86 as of 10:19 AM on Tuesday, Mar 28, a drop of -$0.05, or -5.9% from the previous closing price of $0.91. The stock has traded between $0.79 and $0.91 so far today. Volume today is less active than usual.ROBERT J. JUBA JR. “INOVIO’s team has extensive experience manufacturing DNA medicines and a proven track record of producing them at unprecedented speeds.”. “INOVIO’s CELLECTRA® intramuscular and intracellular smart devices have allowed us to deliver our optimized DNA plasmids directly into cells in the body to produce immune responses. Three months after bringing on a new CEO, Inovio has reached a settlement with investors over accusations that it exaggerated progress on its Covid-19 vaccine candidate. The biotech, once claiming ...Inovio (INO) delivered earnings and revenue surprises of 48.28% and 3,880%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Research & Development Center. 10480 Wateridge Circle San Diego, CA 92121 Phone: 858-597-6006J. Joseph Kim, co-founder and former CEO of Inovio Pharmaceuticals. ... Inovio's stock price has fluctuated widely since the start of 2020, trading at a high of $31.63 per share and a low of $1.38.Inovio Pharmaceuticals Stock Forecast. ... According to 1 stock analyst, the 12-month stock price forecast for INO stock stock is $2.00, which predicts an increase of ...1 Wall Street analysts have issued twelve-month target prices for Inovio Pharmaceuticals' stock. Their INO share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 423.3% from the stock's current price.

Nov 1, 2023 · The stock option has an exercise price of $0.36, the closing price of INOVIO's common stock on the Grant Date. The stock option will vest and become exercisable with respect to one-fourth of the shares underlying the stock option vested on the Grant Date, and an additional one-fourth of the shares underlying the stock option on the first ... ROBERT J. JUBA JR. “INOVIO’s team has extensive experience manufacturing DNA medicines and a proven track record of producing them at unprecedented speeds.”. “INOVIO’s CELLECTRA® intramuscular and intracellular smart devices have allowed us to deliver our optimized DNA plasmids directly into cells in the body to produce immune responses. Galectin Therapeutics Inc. 1.99. -0.13. -6.13%. Get Inovio Pharmaceuticals Inc (INO:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Instagram:https://instagram. stock price of eli lillylandlord insurance florida5 year treasury rates chartcvs caremark wegovy Apr 13, 2023 · Shares of Inovio Pharmaceuticals (INO 0.96%) ... There's also the worry the stock could be delisted from the Nasdaq Stock Market if it continues to trade below $1, which would make it more ... roth 401k vs 401k for high income earnersa o smith corporation Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, ... Inovio in August 2020, claiming it exaggerated evidence of its coronavirus vaccine's efficacy in order to boost its stock price. License of electroporation deviceShares Outstanding: As of September 30, 2023, INOVIO had 269.7 million common shares outstanding and 290.6 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting and conversion, as applicable, of its outstanding options, restricted stock units, convertible preferred stock, and convertible … nio stock buy or sell Nov. 01. MT. Maxim Lowers Price Target for Inovio Pharmaceuticals to $5 From $11, Maintains Buy Rating. 2022. MT. RBC Reinstates Inovio Pharmaceuticals at Sector Perform-Speculative Risk, Assigns $4 Price Target, Awaiting 'More Attractive' Entry Point, 'Clearer Path for Value Creation'.Track Inovio Pharmaceuticals Inc (INO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors